Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$501.38M+52.38%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stephen W. Beard
- Sector
- Consumer Defensive
- Industry
- Education & Training Services
- Employees
- 4,754
- Beta
- 0.63
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 4.14
Financials
Revenue
$501.38M+52.4%Net Income
$71.72M+185.2%EBITDA
$117.69M+99.5%Free Cash Flow
$97.15M+11.1%EPS (diluted)
$2.06+402.4%Shares Outstanding (diluted)
34.76M-45.4%Operating Expenses
$188.09MCash & Debt
$406.32MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.95B | $251.57M | $7.18 |
| 2025 | $1.79B | $232.68M | $6.27 |
| 2024 | $1.58B | $136.78M | $3.49 |
| 2023 | $1.45B | $96.93M | $2.27 |
| 2022 | $1.38B | $-162.49M | $-3.36 |
| 2021 | $906.90M | $76.91M | $1.50 |
| 2020 | $1.05B | $202.23M | $3.77 |
| 2019 | $1.01B | $128.77M | $2.20 |
| 2018 | $1.24B | $33.77M | $0.55 |
| 2017 | $1.21B | $122.28M | $1.87 |
| 2016 | $1.84B | $-3.17M | $-0.05 |
| 2015 | $1.91B | $139.90M | $2.08 |
| 2014 | $1.92B | $134.03M | $2.09 |
| 2013 | $1.96B | $106.79M | $1.66 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CVSA's reported EPS growth of 11.9% a year over 13 years.
- EPS in 5 years
- $12.59
- Implied price
- $214.10
- Return from $125.48
- 11.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $106.45 — -15.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 14 | 17 | 20 | 23 |
|---|---|---|---|---|---|
| 1.9% | -7.1% | -2.5% | 1.3% | 4.7% | 7.6% |
| 6.9% | -2.6% | 2.3% | 6.3% | 9.8% | 12.9% |
| 11.9% | 2.0% | 7.0% | 11.3% | 15.0% | 18.2% |
| 16.9% | 6.6% | 11.8% | 16.3% | 20.1% | 23.5% |
| 21.9% | 11.1% | 16.6% | 21.2% | 25.2% | 28.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+0.00%Social Signal Score
Mentions (6)
- Newszacks.com·12d ago·Positive
Here's Why Covista (CVSA) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·19d ago·Positive
Covista (CVSA) is a Top-Ranked Value Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·32d ago·Positive
Here's Why Covista (CVSA) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·33d ago·Positive
Here's Why Covista (CVSA) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·49d ago·Positive
Here's Why Covista (CVSA) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newsseekingalpha.com·52d ago·Positive
Covista: Strong Secular Growth And Operating Leverage Covista is rated BUY, driven by secular healthcare education demand and 12 consecutive quarters of enrollment growth. CVSA's Q4 saw revenue up 9.7% and adjusted EPS up 25.9%, with all segments showing positive operating leverage and margin expansion. Strong cash flows, a declining leverage ratio, and $238m in share repurchases reinforce balance sheet strength and shareholder returns.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $1.83 per share
Typical surprise +11.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$2.09 vs $1.89beat
- Thu, May 7$1.98 vs $1.73beat
- Wed, Jan 28$2.43 vs $2.19beat
- Thu, Oct 30$1.75 vs $1.58beat
- Thu, Aug 7$1.66 vs $1.53beat
- Thu, May 8$1.92 vs $1.65beat
Estimates and results for CVSA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CVSA officers and directors.
- Bought
- $3.8m
- Sold
- $9.2m
4 trades
15 trades
- Gangadharan Manjunathsold
- Beard, Stephen W.sold
- Phelan Robert J.sold
- Beck Douglas G.sold
- Beard, Stephen W.sold
- Phelan Robert J.sold
- Beck Douglas G.sold
- Phelan Robert J.sold
32 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CVSA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.